Literature DB >> 24211866

The activation of p38 and JNK by ROS, contribute to OLO-2-mediated intrinsic apoptosis in human hepatocellular carcinoma cells.

Zhenzhen Zhang1, Chao Zhang2, Ye Ding3, Qian Zhao4, Lifang Yang4, Jingjing Ling4, Ling Liu4, Hui Ji5, Yihua Zhang6.   

Abstract

In this study, we describe that a novel synthesized compound, olean-28,13β-olide 2 (OLO-2), exhibits selective cytotoxic activity via inducing apoptosis in human hepatocellular carcinoma (HCC) cell lines but not normal human hepatic cells in vitro. Exposure of human HCC HepG2 cells to OLO-2 results in significant loss of mitochondrial transmembrane potential (ΔΨm), the release of cytochrome c, the recruitment of B-cell lymphoma 2 (Bcl-2) assaciated X protein (Bax) and the downregulation of Bcl-2. The apoptosis induced by OLO-2 is associated with the activation of caspase-3/9 and the nuclear translocation of apoptosis inducing factor (AIF). Moreover, the increase of phosphorylated p38 and c-Jun N-terminal kinase (JNK) is observed. OLO-2-induced the externalization of phosphatidyl-serine (PS) and the loss of ΔΨm are blocked by p38 inhibitor SB203580 or JNK inhibitor SP600125. In addition, OLO-2 provokes the generation of reactive oxygen species (ROS) in HepG2 cells, while the antioxidant N-acetyl cysteine (NAC) almost completely blocks OLO-2-induced apoptosis and the activation of p38 and JNK. Taken together, the present study demonstrates that OLO-2 exhibits its cytotoxic activity through intrinsic apoptosis via ROS generation and the activation of p38 and JNK. Its potential to be a candidate of anti-cancer agent is worth being further investigated.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Apoptosis; Cytotoxic; Human HCC cells; Mitochondria; OLO-2

Mesh:

Substances:

Year:  2013        PMID: 24211866     DOI: 10.1016/j.fct.2013.10.043

Source DB:  PubMed          Journal:  Food Chem Toxicol        ISSN: 0278-6915            Impact factor:   6.023


  7 in total

1.  Longikaurin E induces apoptosis of pancreatic cancer cells via modulation of the p38 and PI3K/AKT pathways by ROS.

Authors:  Hai-bo Cheng; Yun Bo; Wei-xing Shen; Xian-guo Ren; Jia-ni Tan; Zhi-rong Jia; Chang-Liang Xu
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-03-06       Impact factor: 3.000

2.  Genetic polymorphisms in antioxidant enzyme genes and susceptibility to hepatocellular carcinoma in Chinese population: a case-control study.

Authors:  Song Su; Kai He; Jing Li; Jiali Wu; Mengyu Zhang; Chunhong Feng; Xianming Xia; Bo Li
Journal:  Tumour Biol       Date:  2015-04-19

3.  PX-12 inhibits the growth of hepatocelluar carcinoma by inducing S-phase arrest, ROS-dependent apoptosis and enhances 5-FU cytotoxicity.

Authors:  Guang-Zhen Li; Hui-Fang Liang; Bo Liao; Lei Zhang; Ya-An Ni; Hong-Hao Zhou; Er-Lei Zhang; Bi-Xiang Zhang; Xiao-Ping Chen
Journal:  Am J Transl Res       Date:  2015-09-15       Impact factor: 4.060

4.  Polyphyllin VII induces apoptosis in HepG2 cells through ROS-mediated mitochondrial dysfunction and MAPK pathways.

Authors:  Chao Zhang; Xuejing Jia; Jiaolin Bao; Shenghui Chen; Kai Wang; Yulin Zhang; Peng Li; Jian-Bo Wan; Huanxing Su; Yitao Wang; Zhinan Mei; Chengwei He
Journal:  BMC Complement Altern Med       Date:  2016-02-09       Impact factor: 3.659

5.  Brassinin Inhibits Proliferation in Human Liver Cancer Cells via Mitochondrial Dysfunction.

Authors:  Taeyeon Hong; Jiyeon Ham; Jisoo Song; Gwonhwa Song; Whasun Lim
Journal:  Cells       Date:  2021-02-05       Impact factor: 6.600

6.  Apoptosis Induction by the Total Flavonoids from Arachniodes exilis in HepG2 Cells through Reactive Oxygen Species-Mediated Mitochondrial Dysfunction Involving MAPK Activation.

Authors:  Huimin Li; Jing Chen; Chaomei Xiong; Han Wei; Changchang Yin; Jinlan Ruan
Journal:  Evid Based Complement Alternat Med       Date:  2014-05-28       Impact factor: 2.629

7.  Metformin Promotes Apoptosis but Suppresses Autophagy in Glucose-Deprived H4IIE Hepatocellular Carcinoma Cells.

Authors:  Deok Bae Park
Journal:  Diabetes Metab J       Date:  2015-12       Impact factor: 5.376

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.